East Lyme, CT, United States of America

Andrew Christopher Flick

USPTO Granted Patents = 9 

 

 

Average Co-Inventor Count = 11.9

ph-index = 2

Forward Citations = 13(Granted Patents)


Location History:

  • East Lyme, CT (US) (2017 - 2019)
  • Kirkland, WA (US) (2019 - 2021)
  • Carlsbad, CA (US) (2023)

Company Filing History:


Years Active: 2017-2025

Loading Chart...
Loading Chart...
Loading Chart...
9 patents (USPTO):

Title: Andrew Christopher Flick: A Pioneer in CCR6 Inhibitors

Introduction

Andrew Christopher Flick is a notable inventor based in East Lyme, Connecticut, with a prolific background in pharmaceutical innovations. He has secured a total of eight patents, contributing significantly to advancements in the field of drug development, particularly in the inhibition of CC chemokine receptor 6 (CCR6).

Latest Patents

Flick's latest patents focus on N-substituted-dioxocyclobutenylamino-3-hydroxy-picolinamides, compounds that demonstrate efficacy as CCR6 inhibitors. The innovation details the development of these compounds, which include pharmaceutically acceptable salts or hydrates. These inventions are poised to play a crucial role in treating or preventing various diseases, conditions, or disorders associated with the inhibition of CCR6.

Career Highlights

Andrew Flick has made significant strides in his career at Pfizer Corporation, where he actively engages in research and development. His contributions through eight patents underscore his dedication to medical science and innovation, enhancing treatment options for complex diseases.

Collaborations

Throughout his career, Flick has collaborated with esteemed colleagues such as Mark E. Schnute and Li Huang Xing. These partnerships exemplify the spirit of teamwork essential for driving innovation in pharmaceutical research and development.

Conclusion

In summary, Andrew Christopher Flick stands out as a key inventor in the realm of pharmaceutical chemistry. His work on CCR6 inhibitors signifies a vital step forward in the development of new therapeutic strategies. With continued collaboration and innovation, he is set to leave a lasting impact on the healthcare industry.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…